Ken Griffin Allakos Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$0.54 - $0.92 $9,666 - $16,468	17,900 Added 144.35%	30,300 $19,000
Q2 2024 Aug 14, 2024	BUY	$1.0 - $1.45 $7,200 - $10,440	7,200 Added 138.46%	12,400 $12,000
Q1 2024 May 15, 2024	SELL	$1.02 - $3.23 $55,590 - $176,035	-54,500 Reduced 91.29%	5,200 $6,000
Q4 2023 Feb 14, 2024	BUY	$1.72 - $3.18 $88,752 - $164,088	51,600 Added 637.04%	59,700 $162,000
Q3 2023 Nov 14, 2023	SELL	$2.13 - $5.55 $19,383 - $50,505	-9,100 Reduced 52.91%	8,100 $18,000
Q2 2023 Aug 14, 2023	BUY	$3.6 - $5.25 $16,560 - $24,150	4,600 Added 36.51%	17,200 $74,000
Q1 2023 May 15, 2023	SELL	$4.3 - $8.27 $575,340 - $1.11 Million	-133,800 Reduced 91.39%	12,600 $56,000
Q4 2022 Feb 14, 2023	SELL	$5.66 - $8.42 $289,792 - $431,104	-51,200 Reduced 25.91%	146,400 $1.23 Million
Q3 2022 Nov 14, 2022	BUY	$3.02 - $6.12 $471,422 - $955,332	156,100 Added 376.14%	197,600 $1.21 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $98.3M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.